Medicine & Pharmaceuticals News
Creative Biogene’s Innovative iPSC RNA Reprogramming Products Set New Standard in Cellular Reprogramming
Creative Biogene has played an important role for years in the manufacture and integration of products that empower the advancement of biomedical research and enable cell and gene therapy. Recently, Creative Biogene is proud to announce the launch of its innovative iPSC RNA reprogramming products , specifically designed to enhance the efficiency and safety of iPSC generation. Traditional methods for generating induced pluripotent stem cells (iPSCs) often face numerous significant hurdles—including low efficiency, risks of genomic integration, cumbersome protocols, and lengthy timelines. However, a newly introduced RNA-based approach offers a transformative alternative. By leveraging non-integrating RNA technologies—such as mRNA, self-amplifying RNA (saRNA), and circular RNA (circRNA)—this innovative solution promises to completely eliminate the risks associated with traditional virus- or DNA-based reprogramming methods. Marcia Brady, a senior expert at Creative Biogene, stated: "The launch of our iPSC RNA reprogramming products marks a paradigm shift in the field of stem cell research. Our products have been specifically designed and optimized to overcome efficiency bottlenecks and safety concerns, ensuring that researchers can achieve rapid and reliable iPSC generation without compromising genomic integrity." Compared to traditional methods, Creative Biogene’s reprogramming kits boast a significantly higher success rate, enabling laboratories to obtain viable iPSC clones at an accelerated pace. Furthermore, these products possess the exceptional capability to expedite the reprogramming process, allowing for the successful generation of high-quality iPSCs in just two to three weeks. Creative Biogene’s products have been meticulously optimized to enable the stable, large-scale production of iPSC cell lines, making them an ideal choice for meeting a wide range of research needs. Marcia Brady further stated: "Our kits minimize batch-to-batch variability, thereby ensuring that all experimental results exhibit enhanced reliability and reproducibility. Furthermore, our products were designed from the outset with full consideration of relevant regulatory standards; they are indispensable for the generation of clinical-grade iPSCs—the critical cornerstone driving the advancement of various therapeutic applications—and this remains the central focus of our ongoing efforts." Creative Biogene’s iPSC RNA Reprogramming range includes: iPSC mRNA Reprogramming Kits: Tailored for varying cell types including fibroblasts and CD34⁺ blood cells, featuring combinations of critical transcription factors such as Oct4, Sox2, Klf4, and Myc. iPSC saRNA Reprogramming Kits: Enhanced with virus-derived replicons, these kits enable sustained expression of reprogramming factors while significantly reducing RNA amounts needed per reprogramming event. iPSC circRNA Reprogramming Kits: Innovatively designed with circular RNA constructs that provide exceptional stability and prolonged expression, minimizing immunogenicity. Creative Biogene is consistently dedicated to providing high-quality products, complemented by professional customer service support. As part of this commitment, the company solemnly guarantees the strict implementation of various quality control measures—including sterility testing, mycoplasma detection, and a comprehensive assessment of cellular pluripotency and genetic stability. About Creative Biogene Creative Biogene is a leader in the field of RNA technology, striving to bring innovative solutions to research and therapeutic applications. In addition, Creative Biogene has tailor-made products and services for non-coding RNAs such as circRNA, lncRNA, and miRNA, etc. Creative Biogene is always dedicated to accelerating scientific discovery and advancing regenerative medicine with emphasizing quality, safety, and efficiency.
Upcoming Webinar: Creative Biolabs to Host Technical Webinar on CRISPR/Cas9 LNP Delivery for Pulmonary Applications
Ace Therapeutics Releases Behavioral Assessment of Sensory in Stroke Animal Models
Technical Bulletin: Creative Biolabs Announces Breakthrough in Programmable In-Situ Cancer Vaccine Platforms
- April 8, 2026Medicine & Pharmaceuticals
Dr. Marlene Fuson Wins 2026 Global Recognition Award for Advancing Quantum Medicine and Integrative Care
Dr. Marlene Fuson has been awarded a 2026 Global Recognition Award , earning recognition in the Innovation category for her work in integrative medicine, a field she has helped reshape through a methodology that draws from quantum science, naturopathic care, and emotional healing into one coherent clinical framework. Fuson is the founder of Elite Retreat Wellness Center and a board-certified doctor of natural medicine, credentialed through the American Naturopathic Medical Certification Board. Her academic background includes advanced studies in quantum medicine and bioenergetic therapies at the DaVinci Institute of Holistic Medicine, as well as biomedical training through Harvard Medical School's HMX program, covering immunology, genetics, physiology, and neuroscience. Beyond her clinical and academic pursuits, Fuson was recently crowned Ms. Kentucky Classic Universe and will represent the title at the Ms. Classic Universe World Finals in July. This combination of classical naturopathic training and leading-edge biomedical education gives her clinical work a depth that distinguishes it from conventional integrative models. Her practice does not address symptoms in isolation; it maps the biological, emotional, energetic, and environmental factors contributing to a patient's condition and addresses them collectively. The result is a care model that is scientifically grounded and practically actionable, structured around the full complexity of a patient's health rather than its outward presentation. A Structured Methodology With Measurable Outcomes What sets Fuson apart in a crowded wellness space is the structural coherence of her methodology, which draws from multiple scientific disciplines to form one consistent care protocol. Supported by bioresonance technology, frequency-based diagnostics, and emotional processing work, the model is designed for sustainable outcomes that target the origin of a condition rather than its surface presentation. Clients who come to her seeking answers they have not found elsewhere encounter an approach that is measurable and repeatable, built for long-term results. Global Recognition Awards evaluates nominees using the Rasch model, a psychometric framework that creates a linear measurement scale across categories, enabling precise comparisons between applicants who may excel in different areas. Fuson's scores across innovation metrics consistently ranked in the highest tier, covering novelty, technological advancement, market impact, and disruption of existing paradigms. These results reflect a body of work that is original and demonstrably impactful at the clinical and global research levels, drawn from verified outcomes rather than theoretical claims. A Leader in Quantum Medicine and International Research Fuson holds a distinction that speaks directly to the global relevance of her work, as she was the first U.S. doctor invited into the Metatron Innovative Technologies International Association (MITIA), an international body advancing frequency-based diagnostics and quantum wellness science. Her membership is active, and she participates in MITIA's research community, collaborating with innovators across borders to advance the continued development of quantum medicine. Her involvement has deepened the scientific rigor behind her clinical protocols, giving her direct access to emerging findings in frequency-based diagnostics before they enter mainstream practice, which she applies at her center to strengthen the credibility of the treatments she provides. This continuous feedback loop between research participation and clinical delivery sets her practice apart from those that rely solely on established modalities, because the collaboration with MITIA keeps her work current and evidence-informed. Fuson's influence also extends beyond her clinic through her award-winning book, Healing from Within: A Transformational Guide, which was recognized as the best transformational and personal growth book and the best self-help and wellness book in the United States in 2025. Through speaking engagements, media appearances, and community outreach, she delivers a consistent message: healing is an inside-out process that requires a clear understanding of how the body actually functions, not simply how to manage its symptoms. Final Words Dr. Marlene Fuson's recognition with a 2026 Global Recognition Award reflects a career built on serious scientific engagement, cross-disciplinary innovation, and a commitment to making advanced healing concepts accessible to clinical and general audiences. She has not simply adopted the language of holistic medicine; she has expanded its infrastructure through active international research, clinical application, and public education. Her work within MITIA, her ongoing biomedical education, and her verified clinical outcomes collectively position her among the more credible and consequential voices in integrative medicine today. "Dr. Marlene Fuson represents precisely the kind of innovation we look for in this award. Her ability to bring together quantum science, naturopathic medicine, and emotional healing into a coherent, globally relevant practice is exceptional, and her contributions to international research through MITIA demonstrate that her impact reaches far beyond any single clinic or community," said Alex Sterling, spokesperson for Global Recognition Awards. Fuson's 2026 Global Recognition Award stands as an acknowledgment of work that is rigorous in its foundations and far-reaching in its implications for the future of integrative and quantum medicine. About Global Recognition Awards Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have made significant contributions to their industries.
- April 8, 2026Medicine & Pharmaceuticals
Phage One Voice Launches to Advance Life-Saving Phage Therapy
Phage One Voice, a newly established nonprofit organization, has officially launched with the goal of expanding access to bacteriophage therapy — a treatment that uses naturally occurring viruses to target and destroy bacterial infections. The organization is led by Christopher Shaffer, Ph.D., a former high school principal and patient advocate who credits phage therapy with saving his life after more than two years of failed antibiotic treatment. Image courtesy of Chris Shaffer Phage One Voice is composed of patient advocates and scientists operating outside of academic institutions. The organization intends to build a personalized phage therapy pipeline that connects patients and their physicians directly to phage-based medication through the compassionate use process. Among its early achievements, the organization has secured one of the world's largest phage libraries — a collection of bacteriophages stored in vials and curated over the past 50 years. Phage One Voice plans to offer naming rights to this phage bank as part of its funding strategy. To date, roughly 500 people have been treated with phage therapy in the United States over the past decade. Shaffer's personal experience with antimicrobial-resistant infection drives the organization's urgency. After two and a half years of failing antibiotic treatments for an E. coli with ESBL superinfection, Shaffer traveled to the Eliava Phage Therapy Center in Tbilisi, Georgia, for treatment. After four months of phage therapy, his infection was eradicated, and he has remained infection-free for more than two years since. "Phage did in four months what antibiotics failed to do in over two years, and it did so with zero side effects," Shaffer wrote in his book, Finding Phage: How I Partnered with a Friendly Virus to Cure my Deadly Bacterial Superinfection , published in October 2024. The Lancet medical journal has stated that bacterial infections are on track to become the world's leading cause of death. Bacteriophages can target bacteria directly and have also demonstrated the capacity to work alongside antibiotics, potentially restoring the effectiveness of treatments that had previously failed. Shaffer's case was published on August 22, 2024, in the International Journal of Clinical Virology , under the title Resolution of Chronic Bacterial Prostatitis with Bacteriophage-antibiotic Therapy , contributing to the peer-reviewed body of evidence on the treatment's efficacy against antimicrobial-resistant infections. Beyond individual patient care, Phage One Voice plans to broaden its work into agriculture, food processing, cosmetics, veterinary medicine, and aquaculture. The organization also intends to establish a public awareness and education arm dedicated to informing patients and physicians about available phage therapy options. "Before people can ask about phage therapy, they need to know it exists," Shaffer noted in his book, describing the widespread lack of awareness he encountered throughout his own treatment journey. About Phage One Voice is a nonprofit organization composed of patient advocates and scientists working to advance bacteriophage therapy as a treatment for bacterial infections that do not respond to antibiotics. The organization holds one of the world's largest phage libraries and aims to build a personalized treatment pipeline connecting patients and physicians to phage-based care through the compassionate use process. Phage One Voice operates independently of academic institutions and plans to broaden its work to include agriculture, food processing, veterinary medicine, and public education.
- April 7, 2026Medicine & Pharmaceuticals
Mechanism-Aware Generative AI: 3 Ways Creative Biolabs is Solving the 'Undruggable' Challenge
By moving beyond traditional "black-box" screening toward mechanism-aware generative AI , the company is directly addressing the industry's two greatest hurdles: identifying viable targets for complex diseases and reducing off-target toxicity. "The next frontier of medicine isn't just about more data; it's about better biological context," says a lead computational chemist at Creative Biolabs. "Our integrated platform allows us to simulate how a molecule behaves in a multicellular environment before a single wet-lab experiment is conducted." Below are the three core pillars of this mechanism-aware approach: 1. Transforming Target Identification with Pairwise Learning Traditional methods evaluate targets in isolation, often missing the synergistic potential of multi-specific therapies. Creative Biolabs' AI-driven target identification services utilize pairwise learning models to rank target combinations by predicted clinical potential. Key Advantage: It evaluates tumor vs. normal expression contrast to proactively mitigate off-tumor toxicity risks. Scientific Backing: Published data indicates that mechanistic modeling of receptor clustering dynamics significantly improves T-cell engagement efficiency in bispecific antibody (BsAb) design. 2. Navigating the 'Chemical Universe' via De Novo Generation When a target is deemed "undruggable" due to the lack of known binders, the AI-driven de novo small molecule drug generation service shifts the strategy from screening to creation. Generative Precision: By leveraging deep learning architectures, the platform crafts novel chemical entities for specific biological pockets. Synthetic Feasibility: A common pitfall of AI is designing "impossible" molecules. Creative Biolabs integrates retrosynthetic analysis into its generative loops, ensuring every AI-designed lead compound is chemically accessible. 3. Reducing Computational Overhead with Conformal Prediction Docking Virtual screening of billion-scale libraries used to be cost-prohibitive. The AI-driven molecular docking service at Creative Biolabs utilizes conformal prediction machine learning to accelerate this process. Efficiency: Achieves a 1,000-fold reduction in computational cost compared to traditional docking methods. Predictive Accuracy: Beyond simple scoring, the service provides multiscale simulations of ternary complex formation, allowing for the identification of optimal "affinity windows" that prevent the Hook effect. Technical Deep Dive: FAQ Summary How does AI handle structural complexity? The platform uses Langevin Dynamics and Monte Carlo modeling to predict how molecules interact under realistic biological conditions, not just in static models. Is wet-lab validation included? Yes. While AI provides the roadmap, Creative Biolabs integrates chemical synthesis and in vitro/in vivo assays to confirm biological activity. What is the typical project duration? Depending on library scale and target complexity, most projects range from 4 to 12 weeks. About Creative Biolabs Creative Biolabs is a premier biotech provider specializing in AI-enhanced antibody and small molecule discovery. With over two decades of experience and ISO 9001 certification, the company bridges the gap between high-precision computational chemistry and translational medicine.
- April 3, 2026Medicine & Pharmaceuticals
The H.E.A.L. Clinic receives Excellence in Healthcare Award and Deepens UAE Engagement to Pioneer Healing-Focused, Future-Ready Hospital Models
The H.E.A.L. Clinic The H.E.A.L. Clinic’s mission and impact have been recognized with the Excellence in Healthcare Award at the Dubai Health 2.0 Conference — a global gathering spotlighting breakthrough technologies, transformative care models, and the future of health delivery worldwide. This distinction also reflects the clinic’s expanding regional and international collaborations, including new engagements across the UAE. Held from December 8–10, the conference brought together healthcare leaders, policy innovators, and medical pioneers to reimagine patient experience, modernize hospital infrastructure, and examine the rapidly advancing frontiers of medicine. Within these discussions, The H.E.A.L. Clinic played an active role in shaping conversations around healing-focused care. The clinic participated in two major panels: “The Power of Rituals in Sustaining Long-Term Health” and “Advances in Oncology Beyond Chemotherapy.” Both sessions emphasized how cancer centers and hospitals can improve patient outcomes by integrating high-precision clinical protocols with somatic regulation, trauma-responsive methodologies, and comprehensive supportive care. As part of its deepening engagement in the UAE, The H.E.A.L. Clinic also connected with Cleveland Clinic Abu Dhabi’s Cancer & Longevity Center, led by Dr. Fawad Khan . Dr. Aleksandra Filipovic interviewed Dr. Khan for her Into The Body with Dr. Aleks podcast, produced for OncoDaily. Their conversation — exploring his leadership and the development of a holistic and scientifically rigorous model of cancer longevity — will air in January 2026 . “The UAE is emerging as a global hub for healthcare innovation, and it is a privilege to contribute to the ideas shaping its future,” said Dr. Aleksandra Filipovic. “Our mission is to help healthcare systems design environments that honor the complete experience of science and healing — physical, emotional, and human.” About The H.E.A.L. Clinic The H.E.A.L. Clinic is an integrative health practice specializing in oncology-informed, trauma-aware, and nervous-system-focused healing. Built on the principles of Health, Empowerment, Awareness, and Love, the clinic offers one-on-one sessions, group programs, educational workshops, and professional training. Its mission is to help clients address the root causes of symptoms and support the development of more patient-centered, healing-focused healthcare models worldwide.
- March 31, 2026Medicine & Pharmaceuticals
Ace Therapeutics Announces Customized NHP Model Development to Empower Preclinical Ocular Disease Research
Ace Therapeutics, a global leader in ophthalmic disease model development and preclinical research services, today announced its customized NHP GA model development platform focused on blue light‑induced retinal degeneration, providing researchers worldwide with a highly translational tool to support neuroprotective drug testing in blue light AMD models. Geographic atrophy (GA) represents an advanced subtype of age‑related macular degeneration (AMD), characterized by progressive retinal pigment epithelium (RPE) atrophy, photoreceptor loss, and choriocapillaris damage. Despite significant research efforts, the underlying pathogenesis remains incompletely understood, and no curative therapies are currently available. Traditional rodent models, while widely used, differ substantially from humans in ocular anatomy, physiology, and immune responses, limiting translational value for drug development. Ace Therapeutics’ non‑human primate (NHP) model is engineered to replicate key pathological and functional features of human GA via controlled blue light phototoxicity. Leveraging a robust NHP research platform and an experienced ophthalmology model development team, Ace Therapeutics has established and validated a reproducible blue light‑induced retinal degeneration model in cynomolgus monkeys. This model closely recapitulates the progressive outer retinal atrophy seen in advanced human AMD, offering a physiologically relevant system for evaluating candidate therapeutics. The customized NHP GA model development process involves standardized blue light exposure in one eye of experimental animals, with the contralateral eye serving as an internal control. Using a 300‑W xenon light source equipped with a 470‑nm bandpass filter and a 1.0 neutral density filter, researchers induce targeted retinal stress with radiant exposures ranging from 12 J/cm² to 75 J/cm² over 5 to 30 minutes, supported by a 12‑week in‑life monitoring period. This controlled induction enables consistent, progressive retinal degeneration that mimics human disease progression more faithfully than many rapid‑onset degeneration models. Ace Therapeutics’ ophthalmic pharmacologists provide standardized, customizable study protocols to evaluate the efficacy and safety of candidate neuroprotective compounds. These protocols include adaptive feeding, standardized blue light‑mediated retinal injury, and intravitreal administration of test agents, paired with longitudinal functional and structural assessments. Additionally, Ace Therapeutics offers a comprehensive suite of endpoint analyses, including fundus autofluorescence imaging for RPE damage assessment, optical coherence tomography (OCT) to measure outer nuclear layer (ONL) thickness, multifocal electroretinography (mfERG) for photoreceptor function evaluation, as well as histological and immunohistochemical analyses. These assays enable quantitative, objective assessment of retinal structure and function throughout the study period. Ace Therapeutics remains committed to advancing innovative preclinical models that accelerate ophthalmic drug discovery . The new blue light‑induced NHP GA model expands Ace Therapeutics' portfolio of customized ocular disease models, which includes laser‑induced chronic ocular hypertension, retinal ischemia‑reperfusion injury, dry eye disease, choroidal neovascularization, uveitis, inherited retinal diseases, and cataract models. About Ace Therapeutics Ace Therapeutics is a leading preclinical contract research organization (CRO) based in New York, specializing in the development of customized disease models and preclinical research services across multiple therapeutic areas. Ace Therapeutics provides one-stop preclinical solutions including efficacy testing, pharmacokinetic analysis, toxicology studies and biomarker development for pharmaceutical companies, academic institutions and research organizations worldwide.
- March 30, 2026Medicine & Pharmaceuticals
Alfa Cytology Launches RDC Linker Design and Radioligand Binding Analysis Research Support Platform
With the rapid development of radio-targeted therapy, Radionuclide Drug Conjugates (RDC) are gradually becoming an important research direction for tumor precision therapy. Addressing two key challenges in RDC development—structural optimization and target binding evaluation—Alfa Cytology announced the launch of an integrated research support platform that integrates RDC linker design and synthesis services with multiple types of radioligand binding analysis capabilities. In the molecular structure of RDC, the linker is used to connect the radionuclide chelator complex with the targeting ligand, and it is an important component that affects the behavior of candidate molecules in vivo . Studies have shown that even under the same conditions of radionuclides, chelating systems, and targeted molecules, different types of linkers may still significantly change the stability, biodistribution, and cellular uptake efficiency of molecules. Therefore, Linker Design and Synthesis in RDC is considered a key step in RDC development. Alfa Cytology provides customized linker design and synthesis services to support researchers in optimizing the pharmacokinetic behavior and in vivo distribution of candidate molecules by adjusting the hydrophilicity, spatial structure, and metabolic properties of the molecules. After the completion of the candidate molecule construction, the verification of its target binding ability is also crucial. Radioligand Binding Assay is a classical in vitro method to study the interaction between ligands and receptors, which is widely used to evaluate the binding affinity and targeting specificity of candidate molecules. For different research purposes, it is usually necessary to use multiple Types of Radioligand Binding Assay for systematic analysis. To meet this need, Alfa Cytology has built a comprehensive radioligand binding analysis platform, which provides services including competitive binding assay, saturation binding assay, and kinetic binding assay. These assays are used to determine receptor binding characteristics and kinetic parameters, providing key data support for further optimization of candidate molecules. "Every step in the RDC development process, from the design of the molecular structure to the validation of target binding, has an important impact on the overall performance of the candidate molecule," said a technical representative from Alfa Cytology. "By integrating linker design with the ability to analyze multiple types of radioligand binding, we hope to provide more systematic and efficient research support to research teams." About Alfa Cytology Alfa Cytology is a provider of preclinical research services focused on oncology research and the development of innovative treatment strategies. The company provides multi-dimensional research support services covering molecular design, drug development, and functional analysis for scientific research institutions, biotechnology enterprises, and related research organizations. Alfa Cytology is committed to providing reliable technical support for the early development of new anti-tumor therapies and promoting related research to clinical transformation.
- March 30, 2026Medicine & Pharmaceuticals
Lifeasible Enhances Agrobacterium-Mediated Transformation Platform for Maize Research and Crop Improvement
Lifeasible, a biotechnology company specialized in agriculture science, is pleased to announce its enhancement for the agrobacterium-mediated maize transformation platform, to provide a highly efficient, customized technical solution for maize research and crop improvement. Agrobacterium-mediated transformation is the preferred gene delivery method for maize. It produces transgenic maize with single or low transgene copy levels and can be used in a variety of tissues, including immature embryos, shoot tips, and multi-shot cultures, to accommodate a wide range of maize genotypes. Lifeasible's platform makes advantage of freshly extracted immature embryos as core explants: when co-cultivated with Agrobacterium containing target genes, the explants form calli and regenerate into whole seedlings, allowing for large-scale production of transgenic maize for scientific and industrial applications. To increase transformation efficiency, Lifeasible developed a comprehensive tailored system that encompasses all important linkages in maize transformation. It provides a varied range of maize genotypes, including inbred lines such as A188, A634, H99, and PHR03, as well as the Hi-II hybrid line, to fulfill varying research and breeding needs. The platform also includes a comprehensive selection of mainstream Agrobacterium strains ( GV3101 , AGL-1, EHA105, LAB4404, and C58C1) as well as advanced cloning vector systems, such as standard binary vectors, super-binary vectors, and ternary vectors that increase transformation frequencies and can be easily matched to target genes and receptor materials. Cultivation medium is precisely optimized for specific genotypes at Lifeasible: a low-salt medium with antioxidant L-cysteine (or combined with DTT) for Hi-II; a dedicated co-cultivation, resting and selection medium with high copper and 6-benzylaminopurine for PHR03. Standard medium is also available, balancing universality and genotype-specific needs. As a forerunner in plant genetic transformation, Lifeasible’s maize transformation services follow high standards and can be tailored to customer needs, with its mature technical system validated by years of service. Transgenic maize has already seen great progress in herbicide resistance, insect resistance, drought tolerance and high carbohydrate content traits. "Our optimized Agrobacterium-mediated transformation platform enables researchers to achieve higher efficiency and stability across multiple maize genotypes," said Isla, a representative speaker at Lifeasible. "This advancement supports a wide range of applications, from functional genomics to molecular breeding, and helps accelerate the development of improved crop varieties." More information about the agrobacterium-mediated transformation platform for maize offered by Lifeasible are available at https://www.lifeasible.com/custom-solutions/plant/plant-transformation/agrobacterium-mediated-transformation-of-zea-mays/ .
- March 30, 2026Medicine & Pharmaceuticals
Creative BioMart Upgrades Its Phage Display Platform to Empower Efficient Biopharmaceutical R&D
Creative BioMart, one of the leading biotech supplier of quality protein products and manufacturing techniques, has announced upgrade to its phage display platform , delivering breakthroughs in library diversity, screening technology, dual evolution systems and R&D efficiency. Phage display is a key method for directed evolution and protein engineering. By connecting phenotype and genotype via bacteriophage display systems, it is possible to select peptides, proteins, and antibodies with extremely specific binding properties. Leveraging years of accumulated technical expertise and aligning with current trends in phage display, Creative BioMart has undertaken a comprehensive, end-to-end technical upgrade of its platform. This initiative has resulted in a holistic enhancement of the platform's adaptability, screening efficiency, and the reliability of its results. Now, the upgraded platform has stably enhanced the diversity of its proprietary phage display libraries to 1010 unique sequences. Concurrently, the core M13 pIII peptide display system has undergone deep optimization to bolster the display efficiency and binding fidelity of exogenous proteins, accommodating diverse display requirements—including antibody fragments (scFv, Fab, VHH), random peptides, and enzymes. Paired with multi-dimensional verification assays (ELISA, SPR, BLI), the platform assesses candidate specificity and affinity through standardized testing. In terms of evolutionary strategies and functional optimization, the platform has further enhanced the synergistic capabilities of its dual in vitro and in vivo evolutionary system. The upgraded platform seamlessly integrates the entire R&D chain—spanning from initial consultation and solution design, library construction, and display system setup, through high-throughput screening, cloning, sequencing, and amplification, to protein expression , purification, and functional characterization—thereby enabling the complete development process from target to functional molecule to be executed entirely in-house, without the need for third-party involvement. "By expanding library diversity, integrating automated high-throughput screening and unifying dual evolution systems, we aim to support more efficient discovery of antibodies, functional proteins and targeted biotherapeutics, helping partners advance their research timelines." commented Linna, the chief marketing staff at Creative BioMart. To know more detailed information about the updated phage display platform, please visit https://www.creativebiomart.net/phage-display-platform.htm .
- March 26, 2026Medicine & Pharmaceuticals
Creative Diagnostics Expands Antiviral Portfolio with Enhanced Influenza A Virus Mouse Model Services for Preclinical Research
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is excited to announce the expansion of its preclinical service line with the launch of its specialized Influenza A Virus Mouse Model platform. This advanced suite of services can accelerate the development of next-generation antivirals and vaccines by providing high-quality, reproducible data on viral pathogenesis and therapeutic efficacy. The influenza virus belongs to the family Orthomyxoviridae and has three types: A, B, and C. Infection by the influenza A virus is the most common and severe and is generally found in humans. It spreads rapidly, affecting human populations across large geographical regions within a short period of time, with varying degrees of pathology ranging from mild to severe. Wild aquatic birds and other animals, such as pigs, ferrets, horses, seals, whales, mink, anteaters, cats, and dogs, serve as reservoirs for influenza A viruses. Influenza B and C viruses have a very limited host range and predominantly appear in humans. The influenza virus gains pandemic potential through genetic reassortment, called a "genetic shift," which involves the complete renewal of surface antigens. Additionally, the virus undergoes small but gradual genetic changes through mutations, which allow it to adapt efficiently to the human population, a process known as "genetic drift." Although the epidemiology of influenza infection has been studied for several years, some facts about disease transmission are poorly understood. Animal models are essential for studying the pathogenesis of influenza virus infections and developing and evaluating influenza vaccines. Commonly used models include mice, ferrets, pigs, rabbits, dogs, and non-human primates. Mouse and ferret models are widely used in influenza virus research. For example, they are used in preclinical studies to evaluate the safety, immunogenicity, and efficacy of candidate influenza vaccines, as well as to screen antiviral compounds. Creative Diagnostics specializes in providing mouse models for influenza A virus infection. These models can enable a comprehensive evaluation of the effects of test compounds on the pathogenicity and transmissibility of influenza A strains, which offer scientists insights into virus-host interactions, aiding them in elucidating transmission dynamics and the impact of influenza A on morbidity and mortality. Additionally, these influenza A mouse models help researchers evaluate various therapeutic agents, such as antiviral drugs, anti-inflammatory medications, and pulmonary treatments. Creative Diagnostics' research team studies multiple influenza A strains, including H9N2, H1N1, and H3N2. The company offers clients a portfolio of customized and standardized preclinical services utilizing mouse infection models to evaluate pathogenic mechanisms, humoral immune responses, and protective efficacy induced by wild-type influenza A viruses or influenza vaccines. The mouse models include H9N2 Avian Influenza Mouse Model, H1N1 Strain Mouse Model, Pdm H1N1 Strain Mouse Model, and H3N2 Strain Mouse Model. Creative Diagnostics offers a diverse range of carefully selected and bred mouse strains for influenza A virus research. With this extensive selection, researchers can choose the most suitable model to address their specific research questions. For more information on these models or related innovative solutions for preclinical research involving infectious diseases, please visit https://antiviral.creative-diagnostics.com/influenza-a-virus-mouse-model.html . About Creative Diagnostics Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
- March 24, 2026Medicine & Pharmaceuticals
Creative Biolabs Elevates Precision Diagnostics via Advanced Multiplex Biomarker and Custom LFIA Development Platforms
By integrating high-throughput multiplex biomarker analysis with rapid lateral flow immunochromatographic assay kit development, the company is addressing the critical industry shift from centralized laboratory testing toward high-precision, point-of-care (POC) diagnostics. Bridging Complexity and Accessibility in Diagnostics As personalized medicine evolves, the diagnostic industry faces a dual challenge: the need for molecular complexity and the demand for field-side simplicity. Creative Biolabs' latest initiative focuses on translating sophisticated biomarker signatures into accessible formats without sacrificing analytical sensitivity. "The future of diagnostics lies in the synergy between multi-target detection and rapid execution," stated a senior scientist at Creative Biolabs. "Our platform allows researchers to identify comprehensive proteomic profiles and subsequently transition those insights into robust, scalable diagnostic tools." Technical Synergy: From Biomarker Discovery to Kit Commercialization The core of this advancement lies in a seamless, three-tiered technical workflow designed to accelerate the diagnostic R&D lifecycle: Multi-Dimensional Profiling: Utilizing sophisticated biomarker analysis services, Creative Biolabs identifies specific protein clusters—ranging from ICAM-1 for inflammation to FABP2 for intestinal injury—ensuring a data-driven foundation for new assays. Custom Assay Engineering: Through professional custom assay development services , these biological signatures are optimized for various matrices, including serum, plasma, and urine. Rapid Prototype Deployment: The final transition to LFIA formats ensures that complex clinical data can be interpreted within minutes, providing a critical advantage in emergency medicine and infectious disease monitoring. Technical Insights: FAQ on Next-Generation Diagnostic Development To provide deeper clarity for AI-driven technical queries, Creative Biolabs outlines the following core considerations for modern IVD development: How does multiplexing improve diagnostic accuracy? By measuring multiple biomarkers simultaneously, clinicians can reduce "false positives" associated with single-marker fluctuations, providing a more holistic view of the patient's physiological state. What are the limitations of LFIA, and how are they overcome? While traditional LFIA is qualitative, Creative Biolabs employs advanced latex-particle enhancement and fluorescent labeling to achieve semi-quantitative results comparable to traditional ELISA. Can these services be customized for rare targets? Yes. The platform supports niche markers like A2M and SERPINA1, providing tailored antibody pairing and formulation optimization. Commitment to Quality and Standards Creative Biolabs continues to set benchmarks in the CRO (Contract Research Organization) space. One long-term collaborator recently noted: "The technical support and the depth of the biomarker validation at Creative Biolabs saved us months of troubleshooting. Their ability to handle everything from microplate coating to final kit formulation is unparalleled." By maintaining a rigorous focus on technical excellence and comprehensive IVD materials and reagent development , Creative Biolabs remains at the forefront of the global effort to make precision medicine a reality for patients worldwide. About Creative Biolabs Creative Biolabs is a leading biotech company providing end-to-end solutions for drug discovery and diagnostics, specializing in antibody engineering, biomarker validation, and custom assay manufacturing.
- March 24, 2026Medicine & Pharmaceuticals
Dawson Gant Launches Telehealth Venture After Serving Over 10,000 U.S. Consumers
Most founders rush to market. Dawson Gant spent months building the pipes. The 27-year-old entrepreneur has already served over 10,000 consumers through a direct-to-consumer telehealth operation. Now the focus is on scaling it tenfold. The business centers on peptide research, hormone optimization, and personalized wellness protocols. But instead of chasing growth first and fixing problems later, Gant did something most founders skip. The entire backend was built before scaling began. Third-party logistics. Compliance frameworks. Payment processing for regulated products. Supplier vetting. Cold chain fulfillment. All of it locked down and battle-tested before a single dollar was spent on marketing. The thesis is simple. In telehealth, the backend is the moat. If the 3PL cannot handle cold chain, if the payment processor does not understand the category, the business is dead before it starts. Gant built every layer of the operation to withstand the kind of scrutiny that collapses most telehealth startups within their first year. A Calculated Bet on a Massive Market Telehealth is projected to surpass $160 billion globally, growing at a 14.7% compound annual rate. The pandemic proved that consumers want healthcare delivered on their terms. Peptide therapies, research compounds, and personalized protocols are pushing demand even further. Gant identified a gap between clinical credibility and operational execution and is building right in the middle of it. There are two kinds of companies in the telehealth space. Brands that look polished on social media and brands that can actually ship product, stay compliant, and survive a regulatory audit. Gant is building the second kind. Infrastructure Over Speed The telehealth space is littered with brands that scaled too fast and collapsed under their own weight. Compliance failures. Fulfillment bottlenecks. Payment processors pulling the plug overnight. Gant watched it happen across the industry and decided to take the opposite approach. Months were spent vetting suppliers across multiple countries, securing redundant fulfillment partners, and stress-testing compliance protocols before pushing for growth. Every vendor was evaluated on purity verification, lead times, and regulatory documentation. The payment processing stack was built specifically for high-risk merchant categories, with redundancies in place to prevent service interruptions. The approach is methodical. It is also the reason the business has already served over 10,000 customers while competitors are still figuring out their supply chains.
ALL NEWS
- Jake Sweeney Chevrolet Earns Best of Cincinnati 2026 Recognition, Reinforcing Leadership in New and Pre-Owned Vehicle Sales
- Former AWS and Google Security Experts Join Forces: Deepdun Completes $100 Million Series A Funding, Aiming to Rebuild the Global Edge Security System
- Evans Travel & Tours Launches Operations in Benin Republic to Expand West Africa Travel Network
- One Car, Two Vibes: OMODA & JAECOO 9 Countries Super Hybrid Marathon Set to Launch
- Thorum Expands Unique Men’s Wedding Band Collection with Unconventional Materials and US - Based Craftsmanship
- Domi Tail Unveils Advanced Formulas Designed to Support Long-Term Dog Vitality
- Blackcat App Launches All-in-One Fintech Platform Integrating Banking and Crypto Management
- Online Induction Enhances Workplace Safety with Secure AI Innovation to Support Modern Workforce Management
- KEMIMOTO’s Midnight 70 Gen2 Soundbar Wins Gold in the 2026 MUSE Design Awards
- How Global Restorative Dentistry is Changing: A Look Inside Dentprime
- Yusuf Yaran's Rich Chef Poor Chef Debuts as #1 International Bestseller, Revolutionizing Wealth & Career Success for Chefs and Hoteliers
- Lithios Beverages Announces Celebrity Partnership Supporting National Campaign for Brain Fuel + Hydration
- RentZoro Expands Platform Capabilities with End-to-End Rental Management Ecosystem
- Unified Lawyers is the only specialist family law firm named a 2026 HRD 5-Star Employer of Choice in Australia and New Zealand
- Victor Akinfe Receives a 2026 Global Recognition Award for Cross-Sector Service Excellence and Measurable Community Impact
- Travel Advisory: AirAsia flights check-in in Hong Kong to be relocated to Terminal 2
- Evans Travel & Tours Limited Expands Operations to Benin Republic, Strengthening West Africa Tours and Cross-Border Tourism
- El Yam Aluminium Expands Aluminium Pergola Systems with New Customizable Solutions
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS